The basic science of botulinum toxin

Facial Plastic Surgery Clinics of North America

Volumn 11, Issue 4, 2003, Pages 431-438

  Lam, Samuel M ^a  

^a Ambulatory Plastic Surgery Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN F; UNCLASSIFIED DRUG;

ARTICLE; BLEPHAROSPASM; BOTULISM; CLINICAL TRIAL; CLOSTRIDIUM; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSPHAGIA; DYSTONIA; HUMAN; LD 50; LEG MUSCLE; MOUSE; MUSCLE DISEASE; MUSCLE WEAKNESS; NONHUMAN; PTOSIS; XEROSTOMIA;

EID: 0346496316     PISSN: 10647406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1064-7406(03)00073-7     Document Type: Review

References (51)

1. Swaminathan S, Eswaramoorthy S. Crystal structure of Clostridium botulinum neurotoxin serotype B. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 29-39.
2. Rossetto O, Caccin P, Rigoni M, Seveso M, Tonello F, Montecucco C. The metalloproteases activity of tetanus and botulinum neurotoxins. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 3-10.
3. Arnon SS. Clinical botulism. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 145-50.
4. Holzer VE. Botulism from inhalation. Med Klin 1962; 57:1735-8 [in German].
5. Mezaki T, Kaji R, Kohara N, Kimura J. Development of general weakness in a patient with amyotropic lateral sclerosis after focal botulinum toxin injection. Neurology 1996;46:845-6.
6. Bakheit AMO, Ward CD, Mclellan CL. Generalised botulism-like syndrome after intramuscular injections of botuliunum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
7. Hanson MA, Stevens RC. Structural view of botulinum neurotoxin in numerous functional states. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 11-27.
8. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995;28:423-72.
9. Chen F, Kuziemko G, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 1998;66:2420-5.
10. Lacy B, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998;5: 898-902.
11. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000;7:693-9.
12. Brin MF. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In: Blitzer A, Binder WJ, Boyd JB, Carruthers A, editors. Management of facial lines and wrinkles. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 280-302.
13. Evans GM, Williams RS, Shone CC, Hambleton P, Melling J, Dolly JO. Botulinum type B: its purification, radioiodination and interaction with rat-brain synaptosomal membranes. Eur J Biochem 1986;154:409-16.
14. Kozaki S, Sakaguchi G. Binding to mouse brain synaptosomes of Clostridium botulinum type E derivative toxin before and after tryptic activation. Toxicon 1982; 20:841-6.
15. Simpson LL, DasGupta BR. Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships. J Pharmacol Exp Ther 1983;224:135-40.
16. 125I-labeled botulinum neurotoxins with nerve terminals: II, autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-44.
17. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-5.
18. Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment of blepharospasm. Neurology 1991;41:1800-5.
19. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.
20. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-9.
21. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BF, editor. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press; 1993. p. 651-4.
22. Greene P, Fahn S, Diamon B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-7.
23. Zuber M, Sebald M, Bathien N, Derecondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type-A botulinum toxin: frequency and significance. Neurology 1993;43:1715-8.
24. Siatkowski RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB, et al. Serum antibody production to botulinum-A toxin. Ophthalmology 1993;100:1861-6.
25. Aoki P, Garrett M, Spanoyannis A. BOTOX (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity. Neurology 1999;52(6 Suppl 2):A521-2.
26. Brin MF, Comella C, O'Brien C. An interim analysis of the clinical status of patients receiving current BOTOX (lot 2024 or subsequent lots) for the treatment of cervical dystonia (CD) [abstract]. Mov Disord 2000; 15(Suppl 2):28-9.
27. Aoki KR. Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 103-13.
28. Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996;14:1538-44.
29. Hatheway CG. Immunology of botulinum toxin. New York: Marcel Decker; 1993.
30. Meyer KF, Eddie B. Perspectives concerning botulism. Z Hyg Infectionskr 1951;133:255-63.
31. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-4.
32. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Oliver Dolly J. Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. J Biol Chem 1999;274:36897-904.
33. Sloop RR, Cole BA, Escutin RO. Human response to botalinum toxin injection: type B compared with type A. Neurology 1997;49:189-94.
34. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, Shimizu T, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45:506-8.
35. Dolly JO, Lisk G, Foran PG, Meunier F, Mohammed N, O'Sullivan G, et al. Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 91-102.
36. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 1998;256:135-8.
37. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 41-9.
38. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-72.
39. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
40. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997;48:1440-2.
41. Lange DJ, Brin MF, Greene P, Lovelace RE, Fahn S. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991;14:672-5.
42. Sanders DB, Massey EW, Buckley EG. Botulinum-toxin for blepharospasm: single-fiber EMG studies. Neurology 1986;36:545-7.
43. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997;12:1064-7.
44. Girlanda P, Vita G, Nicolosi C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844-5.
45. Aoki KR. Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 1999;6(Suppl 4):S3-10.
46. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Opthalmol 1997;235:197-9.
47. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
48. Hauser RA, Comella, C, Brashear A. A randomized, multicenter, double-blind, placebo-controlled study of original Botox (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia [abstract]. Mov Disord 2000;15(Suppl 2):30-1.
49. Kessler KF, Skutta M, Bernecke R. Long-term treatment of cervical dystonia with botulinum toxin type A: efficacy, safety, and antibody frequency. J Neurol 1999;246:265-74.
50. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-40.
51. Callaway JE, Grethlein AJ. Production, quality and stability of botulinum toxin type B (Myobloc) for clinical use. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 115-22.